Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab
Abstract The checkpoint inhibitor nivolumab is active in patients with metastatic melanoma who have failed ipilimumab. In this phase I/II study, we assessed nivolumab's safety in 92 ipilimumab-refractory patients with unresectable stage III or IV melanoma, including those who experienced grade...
में बचाया:
| मुख्य लेखकों: | , , , , , , , , , , , , , |
|---|---|
| स्वरूप: | Artigo |
| भाषा: | अंग्रेज़ी |
| प्रकाशित: |
2016
|
| ऑनलाइन पहुंच: | https://doi.org/10.1158/2326-6066.cir-15-0193 https://cancerimmunolres.aacrjournals.org/content/canimm/4/4/345.full.pdf |
| टैग: |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|
टिप्पणी देने वाले पहले व्यक्ति बनें!